InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

What happened: InnoCare Pharma announced that China's NMPA Center for Drug Evaluation approved its IND application for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for autoimmune diseases including inflammatory bowel disease. Key numbers: Approval announced Oct. 11, 2026. ICP-B161 is InnoCare's fifth novel drug candidate to enter clinical development in 2026. Why it matters: InnoCare said it will accelerate development of ICP-B161 for IBD patients. The company noted no bispecific antibodies targeting TL1A and IL-23p19 have been approved for marketing globally.

InnoCare Pharma announced that China's NMPA Center for Drug Evaluation approved its IND application for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for autoimmune diseases including inflammatory bowel disease.

InnoCare said it will accelerate development of ICP-B161 for IBD patients. The company noted no bispecific antibodies targeting TL1A and IL-23p19 have been approved for marketing globally.